Sclerostin and bone strength in women in their 10th decade of life

Journal of Bone and Mineral Research

Volumn 28, Issue 9, 2013, Pages 2008-2016

  Thorson, Sara ^a   Prasad, Tanushree ^b   Sheu, Yahtyng ^b   Danielson, Michelle E ^b   Arasu, Aarthi ^c   Cummings, Steven R ^d   Cauley, Jane A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d California Pacific Medical Research Institute   (United States)

Author keywords

EPIDEMIOLOGY; OSTEOPOROSIS; QUANTITATION; SCLEROSTIN

Indexed keywords

ESTRADIOL; SCLEROSTIN; TESTOSTERONE;

AFRICAN AMERICAN; AGE; AGED; ANTHROPOMETRIC PARAMETERS; AREAL BONE MINERAL DENSITY; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE SIZE; BONE STRENGTH; BONE TURNOVER; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; EUROPEAN AMERICAN; FEMALE; HIP; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL SYSTEM PARAMETERS; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RACE; TIBIA;

EPIDEMIOLOGY; OSTEOPOROSIS; QUANTITATION; SCLEROSTIN;

ABSORPTIOMETRY, PHOTON; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; COHORT STUDIES; FEMALE; GENETIC MARKERS; HUMANS; OSTEOPOROTIC FRACTURES; TIBIA;

EID: 84882672221     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1929     Document Type: Article

References (38)

1. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L., Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res. 2009; 24: 1651-61.
2. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE., Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011; 26 (12): 2804-11.
3. Padhi D, Jang G, Stouch B, Fang L, Posvar E., Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2010; 26: 19-26.
4. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D., Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23 (6): 860-9.
5. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G., Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25 (5): 248-59.
6. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E., Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int. 2010; 23: 1171-6.
7. Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, Zhou J, Zhang J, Liao E., Serum sclerostin levels were positively correlated with fat mass and bone mineral density in Central South Chinese postmenopausal women. Clin Endocrinol. 2011; 76: 797-801.
8. Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE., Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone. 2012; 51: 153-7.
9. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Muñoz-Torres M., Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2011; 97: 234-41.
10. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ III, Khosla S., Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2010; 26: 373-9.
11. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A., Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2011; 97: 148-54.
12. Spatz JM, Fields EE, Yu EW, Divieti Pajevic P, Bouxsein ML, Sibonga JD, Zwart SR, Smith SM., Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012; 97 (9): E1736-40.
13. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE., Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95: 2248-53.
14. Battaglino RA, Sudhakar S, Lazzari A, Garshick E, Zafonte R, Morse LR., Circulating sclerostin is elevated in short-term and reduced in long-term SCI. Bone. 2012; 51: 600-5.
15. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R., Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012; 97: 1737-44.
16. Arasu A, Cawthon PM, Lui L-Y, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR., Serum sclerostin and risk of hip fracture in older caucasian women. J Clin Endocrinol Metab. 2012; 97 (6): 2027-32.
17. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD., Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013; 24: 489-94.
18. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA., High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the CEOR study. J Bone Miner Res. 2012; 27: 2592-602.
19. Sheu Y, Zmuda JM, Boudreau RM, Petit MA, Ensrud KE, Bauer DC, Gordon CL, Orwoll ES, Cauley JA., Bone strength measured by peripheral quantitative computed tomography and the risk of nonvertebral fractures: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2010; 26: 63-71.
20. Ferretti JL, Capozza RF, Zanchetta JR., Mechanical validation of a tomographic (pQCT) index for noninvasive estimation of rat femur bending strength. Bone. 1996; 18 (2): 97-102.
21. Yu W, Glüer CC, Grampp S, Jergas M, Fuerst T, Wu CY, Lu Y, Fan B, Genant HK., Spinal bone mineral assessment in postmenopausal women: a comparison between dual X-ray absorptiometry and quantitative computed tomgraphy. Osteoporos Int. 1995; 5 (6): 433-9.
22. Schneider P, Reiners C, Cointry GR, Capozza RF, Ferretti JL., Bone quality parameters of the distal radius as assessed by pQCT in normal and fractured women. Osteoporos Int. 2001; 12: 639-46.
23. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R., Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab. 2011; 96: E1159-62.
24. Modder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG, Oursler MJ, Khosla S., Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone. 2011; 49 (2): 202-7.
25. Goebelsmann U, Bernstein GS, Gale JA, Kletzky OA, Nakamura RM, Coulson AH, Korelitz JJ., Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. In:, Lepow IH, CRE, editor Vasectomy: immunologic and pathophysiologic effects in animals and man. New York: Academic Press; p. 165-75. 1979.
26. Goebelsmann U, Arce JJ, Thorneycroft IH, Mishell DR Jr., Serum testosterone concentrations in women throughout the menstrual cycle and following HCG administration. Am J Obstet Gynecol. 1974; 119 (4): 445-52.
27. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, Henderson BE., Aromatase and breast cancer susceptibility. Endocr Relat Cancer. 1999; 6 (2): 165-73.
28. Sodergard R, Backstrom T, Shanbhag V, Carstensen H., Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982; 16 (6): 801-10.
29. Vermeulen A, Verdonck L, Kaufman JM., A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84 (10): 3666-72.
30. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Riboli E, Toniolo P, Kaaks R., Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev. 2002; 11 (10 Pt 1): 1065-71.
31. Sayers SP, Guralnik JM, Newman AB, Brach JS, Fielding RA., Concordance and discordance between two measures of lower extremity function: 400 meter self-paced walk and SPPB. Aging Clin Exp Res. 2006; 18 (2): 100-6.
32. Schoenau E, Neu CM, Rauch F, Manz F., The development of bone strength at the proximal radius during childhood and adolescence. J Clin Endocrinol Metab. 2001; 86: 613-8.
33. Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR., The Study of Osteoporotic Fractures Research Group. Serum sclerostin and risk of hip fracture in older caucasian women. J Clin Endocrinol Metab. 2012; 97: 2027-32.
34. Ardawi MS, Rouzi AA, Qari MH., Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab. 2012; 97 (10): 3691-9.
35. Mödder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG, Oursler MJ, Khosla S., Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone. 2001; 49: 202-7.
36. Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M., Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012; 27 (1): 226-30.
37. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA., Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010; 95 (4): 1991-7.
38. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD., Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013; 24 (2): 489-94.